Evidence map›Paper›PMID 40328099›Full record

SynthesisPsychiatry research2025

Can ketamine and other glutamate receptor modulators be considered entactogens?

Hiroe Hu, Alaina N Tillman, Miyu Fujita, Mayu Yoshikawa, Elizabeth D Ballard, Yoojin Lee, Carlos A Zarate

Abstract readSystematic Review
In one paragraph

Synthesis in Psychiatry research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hiroe HuExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, NIMH-NIH, 10 Center Drive, Bldg. 10, Room 7-5545, Bethesda, MD 20892, USA. Electronic address: hiroe.hu@nih.gov.
Alaina N TillmanExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, NIMH-NIH, 10 Center Drive, Bldg. 10, Room 7-5545, Bethesda, MD 20892, USA.
Miyu FujitaGeorgetown University School of Medicine, Washington, DC, USA.
Mayu YoshikawaTufts University School of Medicine, Medford, MA, USA.
Elizabeth D BallardExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, NIMH-NIH, 10 Center Drive, Bldg. 10, Room 7-5545, Bethesda, MD 20892, USA.
Yoojin LeeExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, NIMH-NIH, 10 Center Drive, Bldg. 10, Room 7-5545, Bethesda, MD 20892, USA.
Carlos A ZarateExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, NIMH-NIH, 10 Center Drive, Bldg. 10, Room 7-5545, Bethesda, MD 20892, USA.

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Intramural NIH HHS Z99 MH999999Intramural NIH HHS ZIA MH002857
6 · The paper itself

Abstract

Subanesthetic-dose ketamine has recently been reported to improve hedonic pleasures associated with social interactions and altruism in individuals with treatment-resistant depression. However, whether ketamine-among other glutamate receptor modulators-also improves empathy and/or prosocial behavior in humans remains unknown. Under a framework grounded in neurobiology that proposes that prosocial behavior is preceded by empathy, this systematic review sought to: (1) explore the entactogenic effects of glutamate receptor modulators observed in clinical trials (as either primary or secondary outcomes), and (2) synthesize the findings regarding which glutamate receptor modulators produce entactogenic effects. Thirty studies that included self-reported ratings, neuroimaging, and/or behavioral task outcomes met inclusion criteria suggesting potential entactogenic effects associated with ketamine and, to less convincing extent, d-cycloserine (DCS). The findings suggest that ketamine and DCS may modulate self- and other-perception, involving changes in activity in brain regions involved in empathetic concerns and mentalizing, the ability to understand one's own and others' thoughts and feelings. These findings may guide potential therapeutic interventions for neuropsychiatric conditions associated with impaired empathy and prosocial behavior, including mood disorders, neurodevelopmental disorders, psychotic disorders, and personality disorders.

Indexed as

EmpathyExcitatory Amino Acid AgentsExcitatory Amino Acid AntagonistsKetamineSocial BehaviorHumansExcitatory Amino Acid AgentsExcitatory Amino Acid AntagonistsKetamined-cycloserineEmpathyEntactogenGlutamate receptor modulatorsKetamineProsocial behavior

Identifiers

PMID40328099
PMCPMC12117387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.